MX2020004214A - Sales de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diaz aspiro[5.5]undecan-3-ona. - Google Patents

Sales de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diaz aspiro[5.5]undecan-3-ona.

Info

Publication number
MX2020004214A
MX2020004214A MX2020004214A MX2020004214A MX2020004214A MX 2020004214 A MX2020004214 A MX 2020004214A MX 2020004214 A MX2020004214 A MX 2020004214A MX 2020004214 A MX2020004214 A MX 2020004214A MX 2020004214 A MX2020004214 A MX 2020004214A
Authority
MX
Mexico
Prior art keywords
difluorophenethyl
undecan
diazaspiro
oxa
salts
Prior art date
Application number
MX2020004214A
Other languages
English (en)
Inventor
Carmen Almansa-Rosales
Nicolas Tesson
Original Assignee
Esteve Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa filed Critical Esteve Pharmaceuticals Sa
Publication of MX2020004214A publication Critical patent/MX2020004214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a sales de (R)-9-(2,5-difluorofen etil)-4-etil-2-metil-1-oxa-4,9-diazaspiro[5.5]undecan-3-ona, a composiciones farmacéuticas que las comprenden, y a su uso en la terapia y/o la profilaxis de enfermedades asociadas con el receptor sigma 5 y/o el receptor ?-opioide.
MX2020004214A 2017-10-17 2018-10-16 Sales de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diaz aspiro[5.5]undecan-3-ona. MX2020004214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382695 2017-10-17
PCT/EP2018/000470 WO2019076475A1 (en) 2017-10-17 2018-10-16 (R) -9- (2,5-DIFLUOROPHENETHYL) -4-ETHYL-2-METHYL-1-OXA-4,9-DIAZASPIRO SALTS [5.5] UNDECAN-3-ONE

Publications (1)

Publication Number Publication Date
MX2020004214A true MX2020004214A (es) 2020-08-13

Family

ID=60201976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004214A MX2020004214A (es) 2017-10-17 2018-10-16 Sales de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diaz aspiro[5.5]undecan-3-ona.

Country Status (21)

Country Link
US (1) US11236110B2 (es)
EP (1) EP3697795B1 (es)
JP (1) JP2020537648A (es)
KR (1) KR20200071107A (es)
CN (1) CN111263764A (es)
AR (1) AR113770A1 (es)
AU (1) AU2018353107B2 (es)
BR (1) BR112020007359A2 (es)
CA (1) CA3076765A1 (es)
CO (1) CO2020005710A2 (es)
DK (1) DK3697795T3 (es)
FI (1) FI3697795T3 (es)
IL (1) IL273751B2 (es)
LT (1) LT3697795T (es)
MA (1) MA50395A (es)
MX (1) MX2020004214A (es)
PH (1) PH12020550104A1 (es)
PT (1) PT3697795T (es)
RU (1) RU2020115274A (es)
SG (1) SG11202002731YA (es)
WO (1) WO2019076475A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021018824A1 (en) * 2019-07-31 2021-02-04 Esteve Pharmaceuticals, S.A. Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
ES2541133T3 (es) 2007-03-01 2015-07-16 Mitsubishi Tanabe Pharma Corporation Compuesto de bencimidazol y uso farmacéutico del mismo
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
UA100400C2 (uk) 2008-02-06 2012-12-25 Астразенека Аб Похідні спіроциклічних амідів
ES2618929T3 (es) 2011-03-14 2017-06-22 Vertex Pharmaceuticals Incorporated Morfolina-Spiro piperidina amida cíclica como moduladores del canal iónico
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
TN2015000474A1 (en) * 2013-04-23 2017-04-06 Esteve Labor Dr PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP2017100951A (ja) * 2014-04-04 2017-06-08 大正製薬株式会社 オキサゾリジノン及びオキサジナノン誘導体
TW201615643A (zh) * 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之１－氧雜－４，９－二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的１－氧雜－４，９－二氮雜螺十一烷化合物之醯胺衍生物
TWI685497B (zh) 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物

Also Published As

Publication number Publication date
IL273751B1 (en) 2023-10-01
SG11202002731YA (en) 2020-05-28
RU2020115274A3 (es) 2022-04-29
DK3697795T3 (da) 2024-02-26
US20200331929A1 (en) 2020-10-22
LT3697795T (lt) 2024-04-10
CN111263764A (zh) 2020-06-09
AU2018353107B2 (en) 2023-07-06
KR20200071107A (ko) 2020-06-18
JP2020537648A (ja) 2020-12-24
FI3697795T3 (fi) 2024-02-23
RU2020115274A (ru) 2021-11-01
EP3697795B1 (en) 2023-11-22
IL273751A (en) 2020-05-31
AU2018353107A1 (en) 2020-04-23
EP3697795A1 (en) 2020-08-26
PH12020550104A1 (en) 2021-01-25
AR113770A1 (es) 2020-06-10
WO2019076475A1 (en) 2019-04-25
PT3697795T (pt) 2024-02-29
CO2020005710A2 (es) 2020-05-29
BR112020007359A2 (pt) 2020-09-29
TW201922752A (zh) 2019-06-16
MA50395A (fr) 2020-08-26
US11236110B2 (en) 2022-02-01
IL273751B2 (en) 2024-02-01
CA3076765A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
SV2018005610A (es) Derivados de oxopiridina sustituidos
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CO2021007908A2 (es) Derivados de oxopiridina sustituidos
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
CL2021000930A1 (es) Piridazinas novedosas
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
BR112019021300A8 (pt) Composições de fragrâncias e produtos com efeitos de melhora do humor
CL2021000580A1 (es) Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares.
MX2020004214A (es) Sales de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diaz aspiro[5.5]undecan-3-ona.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112021011124A2 (pt) Anelossomos e métodos de uso
UY37403A (es) 1–arilnaftiridin–3–carboxamidas 7–sustituidas y su uso
CL2021002483A1 (es) Compuestos y composiciones como moduladores de la señalización tlr
CO2018008626A2 (es) Formulaciones de oritavancina